Bearish: Analysts Just Cut Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Revenue and EPS Estimates
Bearish: Analysts Just Cut Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Revenue and EPS Estimates
The analysts covering Theravance Biopharma, Inc. (NASDAQ:TBPH) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for next year. Both revenue and earnings per share (EPS) estimates were cut sharply as analysts factored in the latest outlook for the business, concluding that they were too optimistic previously.
報道Theravance Biopharma, Inc.(納斯達克股票代碼:TBPH)的分析師今天對明年的法定預測進行了實質性修訂,從而向股東們帶來了一定負面情緒。由於分析師將最新的業務前景考慮在內,得出結論,他們此前過於樂觀,因此收入和每股收益(EPS)的預期均大幅下調。
After this downgrade, Theravance Biopharma's four analysts are now forecasting revenues of US$71m in 2024. This would be a huge 30% improvement in sales compared to the last 12 months. The loss per share is anticipated to greatly reduce in the near future, narrowing 50% to US$0.61. However, before this estimates update, the consensus had been expecting revenues of US$80m and US$0.40 per share in losses. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase.
在這次下調評級之後,Theravance Biopharma的四位分析師現在預測2024年的收入爲7100萬美元。與過去12個月相比,這將使銷售額大幅增長30%。預計每股虧損將在不久的將來大幅減少,縮小50%至0.61美元。但是,在本次估算更新之前,共識一直預計收入爲8000萬美元,每股虧損0.40美元。因此,在最近的共識更新之後,觀點發生了很大變化,分析師大幅下調了收入預期,同時也預計每股虧損將增加。
Check out our latest analysis for Theravance Biopharma
看看我們對Theravance Biopharma的最新分析
The consensus price target was broadly unchanged at US$14.50, perhaps implicitly signalling that the weaker earnings outlook is not expected to have a long-term impact on the valuation.
共識目標股價基本保持不變,爲14.50美元,這可能暗示疲軟的收益前景預計不會對估值產生長期影響。
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. For example, we noticed that Theravance Biopharma's rate of growth is expected to accelerate meaningfully, with revenues forecast to exhibit 23% growth to the end of 2024 on an annualised basis. That is well above its historical decline of 4.8% a year over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in the industry are forecast to see their revenue grow 8.3% per year. So it looks like Theravance Biopharma is expected to grow faster than its competitors, at least for a while.
從現在的大局來看,我們可以理解這些預測的方法之一是看看它們如何與過去的業績和行業增長預期相比較。例如,我們注意到,Theravance Biopharma的增長率預計將大幅加快,預計到2024年底,收入按年計算將實現23%的增長。這遠高於其在過去五年中每年4.8%的歷史下降幅度。相比之下,我們的數據表明,預計該行業其他公司(有分析師報道)的收入每年將增長8.3%。因此,看來Theravance Biopharma的增長速度將超過其競爭對手,至少在一段時間內是如此。
The Bottom Line
底線
The most important thing to note from this downgrade is that the consensus increased its forecast losses next year, suggesting all may not be well at Theravance Biopharma. Unfortunately, analysts also downgraded their revenue estimates, although our data indicates revenues are expected to perform better than the wider market. The lack of change in the price target is puzzling in light of the downgrade but, with a serious decline expected next year, we wouldn't be surprised if investors were a bit wary of Theravance Biopharma.
從此次降級中需要注意的最重要一點是,共識增加了明年的預期虧損,這表明Theravance Biopharma可能並非一切順利。不幸的是,分析師也下調了收入預期,儘管我們的數據顯示收入表現預計將好於整個市場。鑑於評級下調,目標股價沒有變化令人費解,但是,預計明年將出現嚴重下滑,如果投資者對Theravance Biopharma保持警惕,我們也不會感到驚訝。
Still, the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Theravance Biopharma going out to 2025, and you can see them free on our platform here.
儘管如此,該業務的長期前景比明年的收益更爲重要。在Simply Wall St,我們有分析師對Theravance Biopharma到2025年的全方位估計,你可以在我們的平台上免費查看。
Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.
當然,看到公司管理層在股票上投入大量資金與了解分析師是否在下調預期一樣有用。因此,你不妨搜索這份內部人士正在購買的股票的免費清單。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St 的這篇文章本質上是籠統的。我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章並非旨在提供財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不會考慮最新的價格敏感型公司公告或定性材料。華爾街只是沒有持有上述任何股票的頭寸。